Tropical Health and Sustainability

  • J. Kevin BairdEmail author


Tropical health may be considered relevant to the range of human maladies that occur either predominantly in the tropics or become exacerbated by poorly resourced healthcare delivery systems typical of many nations in the tropics. More often, it is both of those factors, as with malaria. Sustainability implies the introduction of novel interventions aimed at mitigating the burdens and risks of such maladies by improving or replacing existing instruments that may be inadequate or suboptimal. Sustainability further implies a design of those instruments amenable to the capacities of those left to use them, following the inevitable retreat of sponsors and their fiscal and technical resources. Further, the instrument must prove effective in mitigating the problem at which it aims. The research and development (R&D) of sustainable technologies against tropical infections represents a relentlessly urgent task, often linked to preventable deaths in very substantial numbers.


Falciparum Malaria Vivax Malaria G6PD Deficiency Verbal Autopsy Malaria Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Artemisinin-combined therapies, a large class of paired drugs that represent the front-line treatments for malaria globally.


Board for the Coordination of Malaria Studies, a US government entity established during World War II and later dissolved to coordinate management of the development of new antimalarial therapies.


Bill & Melinda Gates Foundation.


Case fatality rate, the percentage of patients with a given clinical condition not surviving.


Pesticide ((1,1,1-trichloro-2,2-di(4-chlorophenyl)ethane)), once often used in IRS applications.


Glucose-6-phosphate dehydrogenase, an inherited deficiency of which causes patients to be vulnerable to mild to severe drug-induced acute intravascular hemolysis.


Global Fund for AIDS, Tuberculosis and Malaria, a consortium of International donors committing resources to those health issues.


Global Malaria Eradication Campaign of the 1950s and 1960s.


Good manufacturing practice, a high standard of manufacturing certified by experts.


Indoor residual spraying, in malaria control the practice of spraying the interior walls of homes with insecticide in order to attack mosquitoes that feed on humans.


Insecticide-treated net, or a net that covers a bed at night to protect sleeping people from mosquito bites and malaria infection.


Infection by protozoan parasites (Plasmodium species) carried by mosquitoes, often serious and fatal.


Medicines for Malaria Venture, a public-private partnership committed to developing and licensing new antimalarials therapies.


Generally characterizes global geographic divide between so-called developed and developing nations.


Research and development, deliberate, systematic application of S&T in striving toward specific understanding or objectives.


Rapid diagnostic test, an immunochromatographic, point-of-care kit used at village level to diagnose pathogens (malaria) at low cost.


Science and technology, techniques for expanding understanding of the physical universe.


Technologies or systems that operate effectively in the absence of long-term external financial or technical assistance.

Tropical health

Health issues specific to the tropical zones, especially endemic infectious diseases and underdeveloped healthcare delivery.


World Health Organization.


The Walter Reed Army Institute of Research in Washington, DC, where development of antimalarials by the US government has been supported.



JKB is supported by the Wellcome Trust grant #B9RJIXO. Prof. Jeremy Farrar, Dr. Simon Hay, and Dr. Trevor Jones provided helpful reviews of the manuscript.


Primary Literature

  1. 1.
    Galama T, Hosek J (2008) U.S. competitiveness in science and technology. RAND Corporation, Santa MonicaGoogle Scholar
  2. 2.
    Committee on Ensuring the Best Presidential and Federal Advisory Committee Science and Technology Appointments, National Academy of Sciences, National Academy of Engineering, Institute of Medicine (2005) Science and technology in the national interest: ensuring the best presidential and federal advisory committee science and technology appointments. The National Academies Press, Washington, DC, p 208Google Scholar
  3. 3.
    Lu C, Schneider MT, Gubbins P, Leach-Kemon K, Jamison D, Murray CJL (2010) Public financing of health in developing countries: a cross-national systematic analysis. Lancet 375:1375–1387PubMedCrossRefGoogle Scholar
  4. 4.
    Sachs J, Malaney P (2002) The economic and social burden of malaria. Nature 415:680–685PubMedCrossRefGoogle Scholar
  5. 5.
    WHO (2010) World malaria report 2010. WHO, GenevaGoogle Scholar
  6. 6.
    Hay SI, Okiro EA, Gething PW et al (2010) Estimating the global clinical burden of Plasmodium falciparum malaria in 2007. PLoS Med 7:e1000290PubMedCrossRefGoogle Scholar
  7. 7.
    Gething PW, Smith DL, Patil AP, Tatem AJ, Snow RW, Hay SI (2010) Climate change and the global malaria recession. Nature 465:342–345PubMedCrossRefGoogle Scholar
  8. 8.
    PATH (2011) Staying the course? Malaria research and development in a time of economic uncertainty. PATH, SeattleGoogle Scholar
  9. 9.
    Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW (2004) The global distribution and population at risk of malaria: past, present, and future. Lancet Inf Dis 4:327–336CrossRefGoogle Scholar
  10. 10.
    NIH (2008) NIAID agenda for malaria, Bethesda, MarylandGoogle Scholar
  11. 11.
    WHO (2008) Global Malaria Action Plan, GenevaGoogle Scholar
  12. 12.
    Nosten F, Luxemburger C, ter Kuile FO, Woodrow C, Eh JP, Chonsuphajaisddhi T, White NJ (1994) Treatment of multi-drug resistant Plasmodium falciparum with a 3-day artesunate-mefloquine combination. J Infect Dis 170:971–977PubMedCrossRefGoogle Scholar
  13. 13.
    WHO (2008) World malaria report. WHO, GenevaGoogle Scholar
  14. 14.
    Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI (2005) The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434:214–217PubMedCrossRefGoogle Scholar
  15. 15.
    WHO (2009) World malaria report. WHO, GenevaGoogle Scholar
  16. 16.
    Hay SI, Okira EA, Gething PW, Patil AP, Tatem AJ, Guerra CA, Snow RW (2010) Estimating the global clinical burden of Plasmodium falciparum malaria in 2007. PLoS Med 6:e1000290CrossRefGoogle Scholar
  17. 17.
    Elyazar I, Hay SI, Baird JK (2011) Malaria distribution, prevalence, drug resistance and control in Indonesia. Adv Parasitol 74:41–175PubMedCrossRefGoogle Scholar
  18. 18.
    Harijanto PN (2010) Malaria treatment using artemisinin in Indonesia. Acta Med Indones 42:51–56PubMedGoogle Scholar
  19. 19.
    Dhingra N, Jha P, Sharma VP et al (2010) Adult and child malaria mortality in India. Lancet 376:1768–1774PubMedCrossRefGoogle Scholar
  20. 20.
    Kochar DK, Saxena V, Singh N et al (2005) Plasmodium vivax malaria. Emerg Inf Dis 11:132–134CrossRefGoogle Scholar
  21. 21.
    Kochar DK, Tanwar GS, Khatri PC et al (2010) Clinical features of children hospitalized with malaria - a study from Bikaner, Northwest India. Am J Trop Med Hyg 83:981–989PubMedCrossRefGoogle Scholar
  22. 22.
    Srivastava S, Ahmad S, Shirazi N, Verma SK, Puri P (2011) Retrospective analysis of vivax malaria patients presenting to tertiary care referral centre of Uttarakhand. Acta Trop 117:82–85PubMedCrossRefGoogle Scholar
  23. 23.
    Sharma A, Khanduri U (2009) How benign is benign tertian malaria? J Vector Borne Dis 46:141–144PubMedGoogle Scholar
  24. 24.
    Barcus MJ, Basri H, Picarima H et al (2007) Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua. Am J Trop Med Hyg 77:984–991PubMedGoogle Scholar
  25. 25.
    Genton B, D’Acremont V, Rare L et al (2008) Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med 5:e127PubMedCrossRefGoogle Scholar
  26. 26.
    Tjitra E, Anstey NM, Sugiarto P et al (2008) Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med 5:e128PubMedCrossRefGoogle Scholar
  27. 27.
    Andrade BB, Reis-Filho A, Souza-Neto SM et al (2010) Severe Plasmodium vivax malaria exhibits marked inflammatory imbalance. Malar J 9:13PubMedCrossRefGoogle Scholar
  28. 28.
    Beg MA, Khan R, Baig SM et al (2002) Cerebral involvement in benign tertian malaria. Am J Trop Med Hyg 67:230–232PubMedGoogle Scholar
  29. 29.
    Lomar AV, Vidal JE, Lomar FP et al (2005) Acute respiratory distress syndrome due to vivax malaria: case report and literature review. Braz J Infect Dis 9:425–430PubMedCrossRefGoogle Scholar
  30. 30.
    Lawn SD, Krishna S, Jarvis JN, Joet T, Macallan DC (2003) Case reports: pernicious complications of benign vivax malaria. Trans R Soc Trop Med Hyg 97:551–553PubMedCrossRefGoogle Scholar
  31. 31.
    Spudick JM, Garcia LS, Graham DM, Haake DA (2005) Diagnostic and therapeutic pitfalls associated with primaquine-tolerant Plasmodium vivax. J Clin Microbiol 43:978–981PubMedCrossRefGoogle Scholar
  32. 32.
    Sternberg GM (1884) Malaria and malarial diseases. Wood, New York, p 329Google Scholar
  33. 33.
    Kitchen SF (1949) Vivax malaria. In: Boyd MF (ed) Malariology, vol II. W.B. Saunders, PhiladelphiaGoogle Scholar
  34. 34.
    Ewing J (1902) Contribution to the pathological anatomy of malarial fever. J Exp Med 6:119–180PubMedCrossRefGoogle Scholar
  35. 35.
    Bassat Q, Alonso P (2011) Defying malaria: fathoming severe Plasmodium vivax disease. Nat Med 17:48–49PubMedCrossRefGoogle Scholar
  36. 36.
    Eldridge WW et al (1925) Treatment of paresis: results of inoculation with the organism of benign tertian malaria. JAMA 84:1097–1101CrossRefGoogle Scholar
  37. 37.
    Ferraro A et al (1927) The malaria treatment of general paresis. J Nerv Ment Dis 65:225–239CrossRefGoogle Scholar
  38. 38.
    Freeman W, Eldridge WW, Hall RW (1934) Malaria treatment of dementia paralytica: results in 205 cases after five to eleven years. South Med J 27:122–126CrossRefGoogle Scholar
  39. 39.
    O’Leary PA, Welsh AL (1933) Treatment of neurosyphilis with malaria: observations on nine hundred and eighty-four cases in the last nine years. JAMA 101:498–501CrossRefGoogle Scholar
  40. 40.
    Fong TCC (1937) A study of the mortality rate and complications following therapeutic malaria. South Med J 30:1084–1088CrossRefGoogle Scholar
  41. 41.
    Krauss W (1932) Analysis of reports of 8,354 cases of IMPF-malaria. South Med J 27:537–541CrossRefGoogle Scholar
  42. 42.
    Nicol WD (1932) A review of seven year’s malarial therapy in general paralysis. J Ment Sci 78:843–866Google Scholar
  43. 43.
    James SP, Nicol WD, Shute PG (1936) Clinical and parasitological observations on induced malaria. Proc R Soc Med 29:27–42Google Scholar
  44. 44.
    Verhave JP (2010) personal communicationGoogle Scholar
  45. 45.
    James SP, Nicol WD, Shute PG (1932) A study of induced malignant tertian malaria. Proc R Soc Med 25:37–52Google Scholar
  46. 46.
    Handayani S, Chiu DT, Tjitra E et al (2009) High deformability of Plasmodium vivax-infected red blood cells under microfluidic conditions. J Infect Dis 199:445–450PubMedCrossRefGoogle Scholar
  47. 47.
    O’Donnell J, Goldman JM, Wagner K et al (1998) Donor-derived Plasmodium vivax infection following volunteer unrelated bone marrow transplantation. Bone Marrow Transplant 21:313–314PubMedCrossRefGoogle Scholar
  48. 48.
    Finkel M (2007) Bedlam in the blood: malaria. National Geographic, July 2007, pp 32–67Google Scholar
  49. 49.
    UN Millennium Project (2005) Coming to grips with malaria in the new millennium. Earthscan, London, p 129Google Scholar
  50. 50.
    US CDC (2011) Grand rounds: the opportunity for and challenges to malaria eradication. MMWR 60:476–480Google Scholar
  51. 51.
    Guerra CA, Howes RE, Patil AP et al (2010) The international limits and population at risk of Plasmodium vivax malaria in 2009. PLoS Negl Trop Dis 8:e774CrossRefGoogle Scholar
  52. 52.
    Baird JK (2004) Resistance to chloroquine by Plasmodium vivax. Antimicrob Agents Chemother 48:4075–4083PubMedCrossRefGoogle Scholar
  53. 53.
    Baird JK (2009) Resistance to therapies for Plasmodium vivax. Clin Microbiol Rev 22:508–534PubMedCrossRefGoogle Scholar
  54. 54.
    Baird JK (2005) Effectiveness of antimalarial drugs. N Engl J Med 352:1565–1577PubMedCrossRefGoogle Scholar
  55. 55.
    Baird JK (2011) Resistance to chloroquine unhinges vivax malaria therapeutics. Antimicrob Agents Chemother 55:1827–1830PubMedCrossRefGoogle Scholar
  56. 56.
    WHO (2009) Rapid diagnostic test performance: results of WHO product testing of malaria RDTs: round 1 (2008). WHO, GenevaCrossRefGoogle Scholar
  57. 57.
    Epstein J, Rao S, Williams F et al (2007) Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. J Infect Dis 196:145–154PubMedCrossRefGoogle Scholar
  58. 58.
    Syafruddin D, Krisin, Asih P et al (2009) Seasonal prevalence of malaria in West Sumba district, Indonesia. Malar J 8:8PubMedCrossRefGoogle Scholar
  59. 59.
    Harris I, Sharrock WW, Bain LM et al (2010) A large proportion of asymptomatic Plasmodium infections with low and sub-microscopic parasite densities in the low transmission setting of Temotu Province, Solomon Islands: challenges for malaria diagnostics in an elimination setting. Malar J 9:254PubMedCrossRefGoogle Scholar
  60. 60.
    WHO (2011) Consideration of mass drug administration for the containment of artemisinin resistant malaria in the Greater Mekong Sub-Region. Report of a consensus meeting, 27–28 Sept 2010, GenevaGoogle Scholar
  61. 61.
    Snow RW, Guerra CA, Mutheu JJ, Hay SI (2008) International funding for malaria control in relation to populations at risk of stable Plasmodium falciparum transmission. PLoS Med 5:e142PubMedCrossRefGoogle Scholar
  62. 62.
    Price RN, Tjitra E, Guerra CA et al (2007) Vivax malaria: neglected and not benign. Am J Trop Med Hyg 77(suppl 6):79–87PubMedGoogle Scholar
  63. 63.
    Baird JK (2007) Neglect of vivax malaria. Parasitol Today 23:533–539Google Scholar
  64. 64.
    Harrison G (1978) Mosquitoes, malaria and man: a history of the hostilities since 1880. John Murray, London, p 314Google Scholar
  65. 65.
    McCullough D (1978) The path between the seas: the creation of the Panama Canal 1870–1914. Simon & Schuster, New York, p 698Google Scholar
  66. 66.
    Takken W, Snellen WB, Verhave JP, Knols BGJ, Atmoswedjono S (1990) Envirnmental measures for malaria control in Indonesia – an historical review on species sanitation, Wageningen Agricultural University Papers 90-7, p 167Google Scholar
  67. 67.
    Killeen GF (2003) Following Soper’s footsteps: northeast Brazil 63 years after eradication of Anopheles gambiae. Lancet Infect Dis 3:663–666PubMedCrossRefGoogle Scholar
  68. 68.
    Coatney GR (1963) Pitfalls in a discovery: the chronicle of chloroquine. Am J Trop Med Hyg 12:121–128PubMedGoogle Scholar
  69. 69.
    Sharma VP (1996) Re-emergence of malaria in India. Indian J Med Res 103:26–45PubMedGoogle Scholar
  70. 70.
    Baird JK (2000) Resurgent malaria at the millennium: control strategies in crisis. Drugs 59:719–743PubMedCrossRefGoogle Scholar
  71. 71.
    Gianessi LP, Puffer CA (1992) Reregistration of minor pesticides: some observations and implications. In: USDA (ed) Inputs situation and outlook report. USDA, Washington, DC, pp 52–60Google Scholar
  72. 72.
    Packard RM (1998) ‘No other logical choice’: global malaria eradication and the politics of international health in the post-war era. Parassitologica 40:217–229Google Scholar
  73. 73.
    WHO (2006) Pesticides and their application for the control of vectors and pests of public health importance, 6th edn. Department of Control of Neglected Tropical Diseases, WHO Pesticide evaluation scheme (WHOPES), Geneva, p 125Google Scholar
  74. 74.
    Roberts DR, Manguin S, Mouchet J (2000) DDT house spraying and re-emerging malaria. Lancet 356:330–332PubMedCrossRefGoogle Scholar
  75. 75.
    Roberts DR, Laughlin LL, Hsheih P, Legters LJ (1997) DDT, global strategies, and a malaria control crisis in South America. Emerg Inf Dis 3:295–302CrossRefGoogle Scholar
  76. 76.
    Attaran A, Maharaj R (2000) Ethical debate: doctoring malaria badly; the global campaign to ban DDT. BMJ 321:1403–1405PubMedCrossRefGoogle Scholar
  77. 77.
    WHO (2007) Position statement: the use of DDT in malaria vector control. Global Malaria Program, GenevaGoogle Scholar
  78. 78.
    N’Guessan R, Boko P, Odjo A, Chabi J, Akogbeto M, Rowland M (2010) Control of pyrethroid and DDT-resistant Anopheles gambiae by application of indoor residual spraying or mosquito nets treated with a long-lasting organophosphate insecticide, chlorpyriphos-methyl. Malar J 9:44PubMedCrossRefGoogle Scholar
  79. 79.
    Protopopoff N, Verhaeghen K, Van Borel W et al (2008) A significant increase in kdr in Anopheles gambiae is associated with an intensive vector control intervention in Burundi highlands. Trop Med Int Health 13:1479–1487PubMedCrossRefGoogle Scholar
  80. 80.
    Czeher C, Labbo R, Arzika I, Duchemin JB (2008) Evidence of increasing Leu-Phe knockdown resistance mutation in Anopheles gambiae from Niger following a nationwide long-lasting insecticide-treated nets implementation. Malar J 7:189PubMedCrossRefGoogle Scholar
  81. 81.
    Grieco JP, Achee NL, Chareonviriyaphap T et al (2007) A new classification system for the actions of IRS chemicals traditionally used for malaria control. PLoS One 2(8):156–167CrossRefGoogle Scholar
  82. 82.
    The Global Fund to Fight AIDS, Tuberculosis and Malaria. Global Fund Policy on Quality Assurance for Pharmaceutical Products: procurement of single and limited source pharmaceuticals. Tenth Board Meeting, Geneva, 21–22 Apr 2005, GF-B10-9, Annex 4, p 47Google Scholar
  83. 83.
    Carrara VI, Zwang J, Ashley EA et al (2009) Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One 4:e4551PubMedCrossRefGoogle Scholar
  84. 84.
    Dundorp AM, Newton PN, Mayxay M et al (2004) Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health 9:1241–1246CrossRefGoogle Scholar
  85. 85.
    White NJ (2010) Artemisinin resistance – the clock is ticking. Lancet 376:2051–2052PubMedCrossRefGoogle Scholar
  86. 86.
    Field JW (1938) Notes on the chemotherapy of malaria. Bulletin from the Institute for Medical Research, Federated Malay States 2:63–81Google Scholar
  87. 87.
    Fiammetta R (2003) The miraculous fever tree: malaria and the quest for a cure that changed the world. Harper Collins, New YorkGoogle Scholar
  88. 88.
    Joy RJT (1999) Malaria in American troops in the South and Southwest Pacific in World War II. Med Hist 43:192–207PubMedCrossRefGoogle Scholar
  89. 89.
    Downs WG, Harper PA, Lisansky ET (1947) Malaria and other insect-borne diseases in the South Pacific Campaign, 1942–1945. II. Epidemiology of insect-borne diseases in Army troops. Am J Trop Med 27:69–89Google Scholar
  90. 90.
    Shannon JA (1946) Chemotherapy of malaria. Bull NY Acad Med 22:345–357Google Scholar
  91. 91.
    Slater LB (2009) War and disease: biomedical research on malaria in the 20th century (Critical issues in health and medicine). Rutgers University Press, New Brunswick, p 272Google Scholar
  92. 92.
    Brosius OT (1927) Section II. Plasmochin in malaria. In: Sixteenth Annual Report. Medical Department, United Fruit Company, Boston, pp 26–81Google Scholar
  93. 93.
    Board for the Coordination of Malaria Studies (1943) Results of study of plasmochin toxicity: cases occurring in large scale use of the drug for suppression and treatment of malaria. Malaria Report No.290. Archive of the National Academy of Sciences, Washington, DCGoogle Scholar
  94. 94.
    Board for the Coordination of Malaria Studies (1943) Study of the curative action of plasmochin in vivax malaria: studies in Army and Navy installations. Malaria Report No. 358. Archive of the National Academy of Sciences, Washington, DCGoogle Scholar
  95. 95.
    Office of the Surgeon General (1943) The drug treatment of malaria, suppressive and clinical. Circular letter No. 153. JAMA 123:205–208CrossRefGoogle Scholar
  96. 96.
    Carson PE, Flanagan CL, Ickes CE, Alving AS (1956) Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 14:103–139Google Scholar
  97. 97.
    Most H et al (1946) Chloroquine for treatment of aute attacks of vivax malaria. JAMA 131:963–967CrossRefGoogle Scholar
  98. 98.
    Schmidt LH et al (1977) Radical cure of infections with Plasmodium cynomolgi: a function of total 8-aminoquinoline dose. Am J Trop Med Hyg 26:1116–1128PubMedGoogle Scholar
  99. 99.
    Burgess RW, Bray RS (1961) The effect of a single dose of primaquine on gametocytes, gametogony and sporogony of Laverania falciparum. Bull World Health Organ 24:451–456PubMedGoogle Scholar
  100. 100.
    Rieckmann KH, McNamara JV, Frischer H, Stockert TA, Carson PE, Powell RD (1968) Gametocytocidal and sporontocidal effects of primaquine and of sulfadiazine with pyrimethamine in a chloroquine-resistant strain of Plasmodium falciparum. Bull World Health Organ 38:625–632PubMedGoogle Scholar
  101. 101.
    Peters W (1987) Chemotherapy and drug resistance in malaria, 2nd edn. Academic, London, p 1100Google Scholar
  102. 102.
    Ockenhouse CF, Magill A, Smith D, Milhous W (2005) History of US military contributions to the study of malaria. Mil Med 170(Suppl 1):12–16PubMedGoogle Scholar
  103. 103.
    Oyediran AB, Heisler M (1999) Malarone donation program. J Travel Med 6(Suppl 1):28–30Google Scholar
  104. 104.
    Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, Chen Q (2000) Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother 44:2100–2108PubMedCrossRefGoogle Scholar
  105. 105.
    Ringwald P, Basco LK (1998) Malarone-donation programme in Africa. Lancet 351:673–674PubMedCrossRefGoogle Scholar
  106. 106.
    Oyediran AB, Ddumba EM, Ochola SA, Lucas AO, Koporc K, Dowdle WR (2002) A private-public partnership for malaria control: lessons learned from the Malarone Donation Programme. Bull World Health Organ 80:817–821PubMedGoogle Scholar
  107. 107.
    Shretta R, Walt G, Brugha R, Snow RW (2001) A political analysis of corporate drug donation: the example of Malarone in Kenya. Health Policy Plan 16:161–170PubMedCrossRefGoogle Scholar
  108. 108.
    Attaran A, Barnes KI, Curtis C et al (2004) WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet 363:237–240PubMedCrossRefGoogle Scholar
  109. 109.
    Cappelini MD, Fiorelli G (2008) Glucose-6-phosphate dehydrogenase deficiency. Lancet 371:64–74CrossRefGoogle Scholar
  110. 110.
    Alving AS, Johnson CF, Tarlov AR, Brewer GJ, Kellermeyer RW, Carso PE (1960) Mitigation of the hemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Plasmodium vivax by intermittent regimens of drug administration. Bull World Health Organ 22:621–631PubMedGoogle Scholar
  111. 111.
    Crockett M, Kain KC (2007) Tafenoquine: a promising new antimalarial agent. Expert Opin Investig Drugs 16:705–715PubMedCrossRefGoogle Scholar
  112. 112.
    Tinley KE, Loughlin AM, Jepson A, Barnett ED (2010) Evaluation of a qualitative enzyme chromatographic test for glucose-6-phosphate dehydrogenase deficiency. Am J Trop Med Hyg 82:210–214PubMedCrossRefGoogle Scholar
  113. 113.
    Khim S, Nguon C, Guillard B, Socheat D, Chy S, Sum S, Nhem S, Bouchier C, Tichit M, Christophel E, Taylor R, Baird JK, Menard D (2011) Performance of the CareStart G6PD deficiency screening test. PLoS One (in press)Google Scholar
  114. 114.
    Pannacciulli I, Tizianello A, Ajmar F, Salvidio E (1965) The course of experimentally induced hemolytic anemia in a primaquine-sensitive Caucasian: a case study. Blood 25:92–95PubMedGoogle Scholar
  115. 115.
    George GN, Sears DA, McCurdy PR, Conrad ME (1967) Primaquine sensitivity in Caucasians: hemolytic reactions induced by primaquine in G6PD deficient subjects. J Lab Clin Med 70:80–93PubMedGoogle Scholar
  116. 116.
    Baird JK, Surjadjaja S (2011) Consideration of ethics in primaquine therapy against malaria transmission. Trends Parasitol 27:11–16PubMedCrossRefGoogle Scholar
  117. 117.
    Shekalaghe S, Drakely C, Gosling R et al (2007) Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate. PLoS One 2:e1023PubMedCrossRefGoogle Scholar
  118. 118.
    Shekalaghe SA, ter Braak R, Daou M et al (2010) In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase deficient (G6PD A-) individuals. Antimicrob Agents Chemother 54:1762–1768PubMedCrossRefGoogle Scholar
  119. 119.
    Butcher GA (1997) Antimalarial drugs and the mosquito transmission of Plasmodium. Int J Parasitol 27:975–987PubMedCrossRefGoogle Scholar
  120. 120.
    Imwong M, Snounou G, Purkittayakamee S et al (2007) Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis 195:927–933PubMedCrossRefGoogle Scholar
  121. 121.
    Baird JK, Hoffman SL (2004) Primaquine therapy for malaria. Clin Infect Dis 39:1659–1667CrossRefGoogle Scholar
  122. 122.
    Coggeshall LT (1952) The treatment of malaria. Am J Trop Med Hyg 1:124–131PubMedGoogle Scholar
  123. 123.
    Trager W, Jensen JB (1976) Human parasites in continuous culture. Science 193:673–675PubMedCrossRefGoogle Scholar
  124. 124.
    Malaria Vaccine Initiative (2011) Fact sheet: the RTS, S malaria vaccine candidate, Mar 2011, Washington, DCGoogle Scholar
  125. 125.
    Sherman IW (2009) The elusive malaria vaccine: miracle or mirage? American Society for Microbiology, Washington, DC, p 391Google Scholar
  126. 126.
    Committee on US Military Malaria Vaccine Research (2006) Battling malaria: strengthening the U.S. military vaccine program. National Academies Press, Washington, DC, p 144Google Scholar
  127. 127.
    Desowitz RS (1993) The malaria capers: tales of parasites and people. W.W. Norton, New York, p 288Google Scholar
  128. 128.
    Doolan DL, Dobano C, Baird JK (2009) Acquired immunity to malaria. Clin Microbiol Rev 22:13–36PubMedCrossRefGoogle Scholar
  129. 129.
    Hviid L (2005) Naturally acquired immunity to Plasmodium falciparum in Africa. Acta Trop 95:270–275PubMedCrossRefGoogle Scholar
  130. 130.
    Marsh K, Forster D, Waruiru C et al (1995) Indicators of life-threatening malaria in African children. N Engl J Med 72:334–336Google Scholar
  131. 131.
    Crompton PD, Pierce SK, Miller LH (2010) Advances and challenges in malaria vaccine development. J Clin Invest 120:4168–4178PubMedCrossRefGoogle Scholar
  132. 132.
    Graves PM, Gelband H (2009) Vaccines for preventing malaria (SPf66). Cochrane Libr 2:1–30Google Scholar
  133. 133.
    Carrington WJ, Deragiache E (1999) How extensive is the brain drain? Finance Dev 36:46–49Google Scholar
  134. 134.
    Carpenter KJ (2000) Beriberi, white rice and vitamin B: a disease, a cause and a cure. University of California Press, Berkeley, p 296Google Scholar
  135. 135.
    Post P, Frederick WH, Heidebrink I, Sato S (eds) (2009) The encyclopedia of Indonesia in World War II. Brill, Leiden, Netherlands, p 710Google Scholar
  136. 136.
    Stone R (2010) Righting a 65-year-old wrong. Science 329:30–31PubMedCrossRefGoogle Scholar

Books and Reviews

  1. Feacham GA, Phillips AA, Targett GA (eds) (2009) Shrinking the malaria map: a prospectus on malaria elimination. University of California San Francisco, Global Health Group, San Francisco, p 187Google Scholar
  2. Lobo L (2010) Malaria in the social context: a study in western India. Routledge, New Delhi, p 213Google Scholar
  3. Packard RM (2007) The making of a tropical disease: a short history of malaria. The Johns Hopkins University Press, Baltimore, p 320Google Scholar
  4. Shah S (2011) The fever: how malaria has ruled humankind for 500,000 years. Picador, New York, p 320Google Scholar
  5. Sherman IW (2010) Magic bullets to conquer malaria: from quinine to qinghaosu. American Society for Microbiology Press, Washington, DC, p 298Google Scholar
  6. Snowden F (2006) The conquest of malaria: Italy, 1900–1962. Yale University Press, New Haven, p 304Google Scholar
  7. Winther PC (2005) Anglo-European science and the rhetoric of empire: malaria, opium and British rule in India 1756–1895. Lexington Books, New York, p 450Google Scholar
  8. Yip K-C (ed) (2009) Disease, colonialism and the state: malaria in modern East Asian history. Hong Kong University Press, Hong Kong, p 161Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Eijkman–Oxford Clinical Research Unit, Jalan DiponegoroJakartaIndonesia
  2. 2.Centre for Tropical Medicine, Nuffield Department of MedicineUniversity of OxfordOxfordUK

Personalised recommendations